TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRAW TRAWS PHARMA

Closed 04-13 16:00:00 EDT

1.61

+0.13

+8.78%

盘后1.60

-0.01-0.62%

19:28 EDT

High1.64	Low1.48	Vol21.74K
Open1.48	D1 Closing1.48	Amplitude10.81%
Mkt Cap12.87M	Tradable Cap9.54M	Total Shares7.99M
T/O34.00K	T/O Rate0.37%	Tradable Shares5.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.61,"timestamp":1776110400000,"preClose":1.48,"halted":0,"volume":21735,"hourTrading":{"tag":"盘后","latestPrice":1.6,"preClose":1.61,"latestTime":"19:28 EDT","volume":1114,"amount":1781.87,"timestamp":1776122884035,"change":-0.01,"changeRate":-0.006211,"amplitude":0.006211},"delay":0,"changeRate":0.08783783783783791,"floatShares":5925700,"shares":7990867,"eps":-1.82,"marketStatus":"Closed","change":0.13,"latestTime":"04-13 16:00:00 EDT","open":1.48,"high":1.64,"low":1.48,"amount":33995.6026515,"amplitude":0.108108,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.82,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776153600000},"marketStatusCode":5,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.48,"preHourTrading":{"tag":"盘前","latestPrice":1.47,"preClose":1.48,"latestTime":"09:29 EDT","volume":1,"amount":1.47,"timestamp":1776086941115,"change":-0.01,"changeRate":-0.006757,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.6,"preClose":1.61,"latestTime":"19:28 EDT","volume":1114,"amount":1781.87,"timestamp":1776122884035,"change":-0.01,"changeRate":-0.006211,"amplitude":0.006211},"volumeRatio":0.363143,"impliedVol":1.6331,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TRAW/wiki","defaultTab":"wiki","newsList":[{"id":"2626192165","title":"Traws Pharma CFO Charles Nolan Parker files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192165","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626192165?lang=en_us&edition=fundamental","pubTime":"2026-04-09 02:46","pubTimestamp":1775673991,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 3 for CFO Charles Nolan Parker, dated July 3, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 08, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nNDLGbKRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624455849","title":"Traws Pharma delays annual report filing, seeks 15-day extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2624455849","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624455849?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:59","pubTimestamp":1774990789,"startTime":"0","endTime":"0","summary":"Traws Pharma filed Form 12b-25 to delay its annual report on Form 10-K for fiscal year ended Dec. 31, 2025.Filing delay tied to additional time needed to assess impact of potential financing on financial statements, including going-concern disclosures.Management reported no financing agreement in place as it works to address Nasdaq minimum stockholders’ equity requirement.Company expects to file Form 10-K within 15-day extension period allowed under SEC rules.Preliminary results point to revenue of $2.8 million; net income seen at about $9.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLb6NVn8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622297758","title":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622297758","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622297758?lang=en_us&edition=fundamental","pubTime":"2026-03-27 20:32","pubTimestamp":1774614726,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc  expected to post a loss of $1.22 a share - Earnings Preview Traws Pharma Inc TRAW.OQ TRAW.O is expected to  show a fall in quarterly revenue when it reports  results on March 30 (est","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F0ZE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612400625","title":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2612400625","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612400625?lang=en_us&edition=fundamental","pubTime":"2026-02-19 21:17","pubTimestamp":1771507073,"startTime":"0","endTime":"0","summary":"BUZZ-Traws Pharma falls after FDA puts flu drug application on clinical hold** Shares of Traws Pharma TRAW.O down 20.81% at $1.58 premarket** Co says the U.S. FDA placed on clinical hold its investigational new drug application for tivoxavir marboxil, a single oral tablet for prevention of seasonal influenza** Adds that FDA flagged concerns \"with the mutagenicity data package\" for drug in application** Also says it filed the application to allow the government's biomedical research unit to fully review its bid for inclusion in the strategic stockpile for avianflu treatment** Clinical hold does not directly impact ongoing and planned studies outside of the United States; working to mitigate issue in clinical development plan - TRAW  ** TRAW shares up 74.3% YTD       ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL4N3ZF0XW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612140749","title":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612140749","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612140749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:58","pubTimestamp":1771505921,"startTime":"0","endTime":"0","summary":"BRIEF-Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid-Eligible And Ineligible Covid-19 Patients Feb 19 (Reuters) - Traws Pharma Inc TRAW.O:TRAWS PHARMA COMPLETES ANALYSIS OF ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612059402","title":"Traws Pharma reports Phase 2 ratutrelvir study results versus Paxlovid in COVID-19 patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2612059402","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612059402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504217,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. reported completion of its clinical analysis from a 90-patient, open-label Phase 2 study evaluating ratutrelvir, an investigational oral ritonavir-free Mpro/3CL protease inhibitor, versus PAXLOVID in mild-to-moderate COVID-19 patients, including a separate single-arm cohort of PAXLOVID-ineligible patients. The company said the analysis found fewer treatment-related adverse events and no viral rebound events in ratutrelvir-treated patients, with equivalent time to sustained symptom resolution versus PAXLOVID; in PAXLOVID-ineligible patients, it reported a shorter time to symptom resolution compared with PAXLOVID. The company also provided preclinical and development updates on tivoxavir marboxil tablets for once-monthly influenza prophylaxis, including plans for a PK study under an open IND in Australia and preparations for a human influenza prophylaxis challenge study in the UK. The ratutrelvir results were presented as completed in the announcement; no future present","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL41fzpr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP","SG9999014021.USD","TRAW","IE00BKPKM429.USD","LU2095319765.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","BK4007","LU0314104364.USD","BK4588","BK4585","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612540274","title":"Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in Paxlovid®-Eligible and Ineligible Covid-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=2612540274","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612540274?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612402749","title":"Traws Pharma Inc - FDA Places Clinical Hold on Tivoxavir Marboxil Ind","url":"https://stock-news.laohu8.com/highlight/detail?id=2612402749","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612402749?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612060402","title":"Traws Pharma Inc: FDA Intends to Communicate Its Concerns Formally, Together With Suggested Mitigation Steps, by March 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2612060402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612060402?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:30","pubTimestamp":1771504201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nTUA11LYLY:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607010262","title":"Traws Pharma initiated with a Buy at Ladenburg","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010262","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607010262?lang=en_us&edition=fundamental","pubTime":"2026-01-30 20:20","pubTimestamp":1769775623,"startTime":"0","endTime":"0","summary":"Ladenburg initiated coverage of Traws Pharma (TRAW) with a Buy rating and $6.50 price target The firm says the company offers an alternative to Cid...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/traws-pharma-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/traws-pharma-initiated-with-a-buy-at-ladenburg-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606439412","title":"Traws Pharma Completes Enrollment in Phase 2 Ratutrelvir COVID-19 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2606439412","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606439412?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:30","pubTimestamp":1769434251,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. announced the completion of enrollment in its Phase 2 clinical study evaluating ratutrelvir, an investigational oral Mpro/3CL protease inhibitor, in comparison to PAXLOVID in patients with mild-to-moderate COVID-19. The study also includes a single arm for patients ineligible to receive PAXLOVID. According to the company, ongoing clinical results indicate ratutrelvir has demonstrated a differentiated profile versus PAXLOVID, with observations of fewer adverse events, absence of viral rebounds, and faster time to sustained symptom resolution. These findings have also been observed in PAXLOVID-ineligible patients. Final results have not yet been presented. Additionally, Traws Pharma provided an update on its tivoxavir marboxil program, indicating that a new compressed tablet formulation may offer 28-day prophylactic protection against a broad range of seasonal and pandemic-potential influenza variants. A human influenza prophylaxis challenge study is scheduled for June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL5jKGpq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4588","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BK4007","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","TRAW","BK4112","NDAQ","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606024346","title":"Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza","url":"https://stock-news.laohu8.com/highlight/detail?id=2606024346","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606024346?lang=en_us&edition=fundamental","pubTime":"2026-01-26 21:30","pubTimestamp":1769434200,"startTime":"0","endTime":"0","summary":"Ongoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/26/3225645/0/en/Traws-Pharma-Completes-Enrollment-of-Ratutrelvir-Clinical-Study-in-PAXLOVID-Eligible-and-Ineligible-COVID-19-Patients-Announces-Plans-for-Added-Indication-for-Tivoxavir-Marboxil-as.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4588","BNTX","BK4218","TRAW","BK4181","BK4568","PK","BK4548","BK4007","BK4551","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603686627","title":"Traws Pharma Files IND Application for Tivoxavir Marboxil Influenza Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686627","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686627?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305620,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has filed an Investigational New Drug  application with the U.S. Food and Drug Administration  for tivoxavir marboxil , an oral CAP-dependent endonuclease inhibitor intended for the treatment of influenza. The filing marks a key step towards formal consideration by the FDA and the Center for the Biomedical Advanced Research and Development Authority  for potential inclusion of TXM in the U.S. strategic national stockpile. No grant or funding involving multiple organizations was mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 13, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDL7pplcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4007","LU0314104364.USD","SG9999014021.USD","IE00BKPKM429.USD","BK4112","BK4588","NDAQ","TRAW","SG9999014013.SGD","IE00BGHQF748.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4585","SG9999014005.SGD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603863946","title":"Traws Pharma Inc: Full Study Enrollment Expected in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863946","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603863946?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305603,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8WSL4L:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603686345","title":"Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (Ind) Application for Influenza Therapy, and Provides Updated Results From the Ongoing Clinical Study of Ratutrelvir in Paxlovid®-Eligible and Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2603686345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603686345?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:00","pubTimestamp":1768305603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA8WSL4L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592399184","title":"Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399184","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592399184?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969221,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via Glob","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL38GghF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4007","BK4585","LU2095319765.USD","LU2210149790.SGD","SG9999014013.SGD","SG9999014039.USD","LU2210150020.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4588","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4112","IE00BKPKM429.USD","SG9999014021.USD","TRAW","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592991829","title":"Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991829?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592991823","title":"Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991823?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592918579","title":"Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918579?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592958804","title":"Traws Pharma Grants Stock Options and RSUs to Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2592958804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592958804?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:01","pubTimestamp":1765922477,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units  under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1wrvY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onconova.com","stockEarnings":[{"period":"1week","weight":-0.0976},{"period":"1month","weight":-0.2563},{"period":"3month","weight":0.1045},{"period":"6month","weight":-0.5083},{"period":"1year","weight":-0.1543},{"period":"ytd","weight":0.3097}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.538462,"avgChangeRate":0.179894},{"month":2,"riseRate":0.384615,"avgChangeRate":-0.08728},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.040526},{"month":4,"riseRate":0.230769,"avgChangeRate":-0.137265},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.059914},{"month":6,"riseRate":0.75,"avgChangeRate":0.06745},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019463},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.120142},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.103896},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.080722},{"month":11,"riseRate":0.461538,"avgChangeRate":-0.058331},{"month":12,"riseRate":0.307692,"avgChangeRate":0.009577}],"exchange":"NASDAQ","name":"TRAWS PHARMA","nameEN":"TRAWS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRAWS PHARMA,TRAW,TRAWS PHARMA股票,TRAWS PHARMA股票老虎,TRAWS PHARMA股票老虎国际,TRAWS PHARMA行情,TRAWS PHARMA股票行情,TRAWS PHARMA股价,TRAWS PHARMA股市,TRAWS PHARMA股票价格,TRAWS PHARMA股票交易,TRAWS PHARMA股票购买,TRAWS PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction